Resultados clínicos de um ano do registro POLAR (Promus eluting stent registry in Latin America)

• Autor(a) principal: Souza, Cristiano Freitas de [UNIFESP]
• Data de Publicação: 2012
• Outros Autores: Costa Jr., J. Ribamar, Abizaid, Andrea, Ferreira, Esmeralci, Perin, Marco Antonio, Barbosa, Flávio Passos, Mangione, José Armando, Costantini, Costantino R., Arruda, José Airton de, Salvadori Jr., Décio, Serpa, Renato Giestas, Sarmento-Leite, Rogério, Abizaid, Alexandre Antonio Cunha [UNIFESP], Feres, Fausto
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1590/S2179-83972012000100007; http://repositorio.unifesp.br/handle/11600/7026
• topic: Drug-eluting stents; Coronary restenosis; Coronary thrombosis; Stents farmacológicos; Reestenose coronária; Trombose coronária

BACKGROUND: Drug-eluting stents have been used since 2002 in different patient populations aiming to achieve high success rates with low clinical and angiographic restenosis rates. With the late thrombosis adverse events associated to the first generation sirolimus and paclitaxel-eluting stents, second-generation everolimus and zotarolimus-eluting stents has been recently developed. METHODS: The POLAR registry is a prospective, non-randomized, multicenter study, which included 988 patients, totaling 1,362 lesions treated with the everolimus-eluting stent Promus®. In order to represent the clinical practice, almost all subtypes of patients and lesions were included in this registry. Clinical follow-up was planned to be performed 1, 6, 12 and 24 months after the procedure. RESULTS: Most patients were male (69.8%), with mean age of 64.9 ± 9.4 years, 35.2% were diabetics and 55% had been treated for acute coronary syndrome. Vessel diameter was 2.95 ± 0.43 mm and lesion extension was 20.5 ± 5.6 mm. A total of 1.14 ± 0.38 stent/patient were implanted and the procedural success rate was 96.6%. Major adverse cardiac events occurred in 4.5% of patients, and stent thrombosis was observed in 5 patients (0.5%) after a clinical follow-up of 12 months. CONCLUSIONS: The present registry suggests that everolimus-eluting stents are safe and effective in daily clinical practice patients, with a low rate of major adverse cardiac events at the end of the first year of follow-up.